Acquisition Opportunity Potential post-acquisition integration for Pyros Pharmaceuticals following Bora Corp's announced acquisition, with sales teams focusing on cross-sell of rare pediatric disease therapies and existing patient support programs to broaden product portfolio and distribution reach.

Rare Disease Focus Target opportunities in rare pediatric indications and niche delivery challenges where Pyros currently operates, leveraging partnerships with specialty pharmacies like AnovoRx to expand access and drive payer-friendly solutions.

Strategic Partnerships Leverage Pyros collaborations and tech stack familiarity to propose integrated solutions for patient support, digital marketing attribution, and streamlined contracting with NetSuite and DocuSign to reduce sales cycle friction.

Market Entry Readiness Supplement growth by aligning with smaller specialty distributors and clinics serving underserved populations, using Pyros' affordability and accessibility positioning to differentiate in competitive biosimilars and niche therapies.

Funding & Scale Explore co-development or co-funding opportunities given current revenue range and modest funding; highlight potential upside from expanding rare disease portfolios to attract co-investors and accelerate commercialization post-acquisition.